Published in Structure on November 08, 2012
Molecular basis of MAP kinase regulation. Protein Sci (2013) 1.15
Ligand-binding dynamics rewire cellular signaling via estrogen receptor-α. Nat Chem Biol (2013) 0.96
Structure and dynamics of the MKK7-JNK signaling complex. Proc Natl Acad Sci U S A (2015) 0.82
JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships. Microbiol Mol Biol Rev (2016) 0.81
A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases. ACS Chem Biol (2013) 0.81
Systematic discovery of linear binding motifs targeting an ancient protein interaction surface on MAP kinases. Mol Syst Biol (2015) 0.78
Co-conserved MAPK features couple D-domain docking groove to distal allosteric sites via the C-terminal flanking tail. PLoS One (2015) 0.77
Two Hydrophobic Residues Can Determine the Specificity of Mitogen-activated Protein Kinase Docking Interactions. J Biol Chem (2015) 0.75
The crystal structure of JNK from Drosophila melanogaster reveals an evolutionarily conserved topology with that of mammalian JNK proteins. BMC Struct Biol (2015) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
The Protein Data Bank. Nucleic Acids Res (2000) 187.10
PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr (2010) 108.52
MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr (2009) 53.36
Differential regulation and properties of MAPKs. Oncogene (2007) 6.36
Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr D Biol Crystallogr (2011) 6.27
The JNK signal transduction pathway. Curr Opin Cell Biol (2007) 5.86
Atomic structure of the MAP kinase ERK2 at 2.3 A resolution. Nature (1994) 4.97
Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell (1997) 4.26
Scaffold proteins: hubs for controlling the flow of cellular information. Science (2011) 4.00
Modular cell biology: retroactivity and insulation. Mol Syst Biol (2008) 3.11
From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life (2005) 2.79
Docking motif interactions in MAP kinases revealed by hydrogen exchange mass spectrometry. Mol Cell (2004) 2.55
Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J (2004) 2.53
Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. Mol Cell (2002) 2.51
NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat Chem Biol (2008) 2.44
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A (2008) 2.26
Docking interactions induce exposure of activation loop in the MAP kinase ERK2. Structure (2006) 2.01
Requirement of the JIP1 scaffold protein for stress-induced JNK activation. Genes Dev (2001) 1.96
The JNKK2-JNK1 fusion protein acts as a constitutively active c-Jun kinase that stimulates c-Jun transcription activity. J Biol Chem (1999) 1.86
The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. Proc Natl Acad Sci U S A (1997) 1.83
Membrane localization of scaffold proteins promotes graded signaling in the yeast MAP kinase cascade. Curr Biol (2008) 1.66
c-Jun N-terminal kinase (JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor (TNF) requires mitochondrial Sab protein expression in mice. J Biol Chem (2011) 1.57
Tunable signal processing in synthetic MAP kinase cascades. Cell (2011) 1.45
Crystal structure of JNK3: a kinase implicated in neuronal apoptosis. Structure (1998) 1.45
Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. Biochem J (2000) 1.44
Selectivity of docking sites in MAPK kinases. J Biol Chem (2009) 1.36
An essential role of the JIP1 scaffold protein for JNK activation in adipose tissue. Genes Dev (2004) 1.32
Detailed analysis of the free and bound conformations of an antibody. X-ray structures of Fab 17/9 and three different Fab-peptide complexes. J Mol Biol (1993) 1.29
Mitochondrial c-Jun N-terminal kinase (JNK) signaling initiates physiological changes resulting in amplification of reactive oxygen species generation. J Biol Chem (2011) 1.29
Substrate-dependent control of MAPK phosphorylation in vivo. Mol Syst Biol (2011) 1.26
Coupling of receptor conformation and ligand orientation determine graded activity. Nat Chem Biol (2010) 1.25
Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. Mol Cell (2004) 1.24
Activation of JNK3 alpha 1 requires both MKK4 and MKK7: kinetic characterization of in vitro phosphorylated JNK3 alpha 1. Biochemistry (2000) 1.07
Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. J Med Chem (2010) 1.05
Determinants that control the specific interactions between TAB1 and p38alpha. Mol Cell Biol (2006) 1.02
Selective inhibition of mitochondrial JNK signaling achieved using peptide mimicry of the Sab kinase interacting motif-1 (KIM1). ACS Chem Biol (2011) 0.98
Understanding the specificity of a docking interaction between JNK1 and the scaffolding protein JIP1. J Phys Chem B (2011) 0.97
Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson's Disease. ACS Chem Neurosci (2011) 0.96
Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38. J Biol Chem (2009) 0.93
Growth factor stimulation induces cell survival by c-Jun. ATF2-dependent activation of Bcl-XL. J Biol Chem (2010) 0.89
Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3alpha1. Biochemistry (2008) 0.88
Enzyme kinetics and interaction studies for human JNK1β1 and substrates activating transcription factor 2 (ATF2) and c-Jun N-terminal kinase (c-Jun). J Biol Chem (2012) 0.85
Characterization of a novel JNK (c-Jun N-terminal kinase) inhibitory peptide. Biochem J (2011) 0.84
A five-year itch in TNF-alpha cytotoxicity: the time factor determines JNK action. Dev Cell (2006) 0.81
Three-dimensional docking in the MAPK p38α. Sci Signal (2011) 0.79
Requirement of JIP1-mediated c-Jun N-terminal kinase activation for obesity-induced insulin resistance. Mol Cell Biol (2010) 0.78
Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure (2007) 2.57
Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol (2002) 1.83
Discovery of potent and selective covalent inhibitors of JNK. Chem Biol (2012) 1.55
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science (2003) 1.48
Elemental isomerism: a boron-nitrogen surrogate for a carbon-carbon double bond increases the chemical diversity of estrogen receptor ligands. Chem Biol (2007) 1.31
Mitochondrial c-Jun N-terminal kinase (JNK) signaling initiates physiological changes resulting in amplification of reactive oxygen species generation. J Biol Chem (2011) 1.29
Coupling of receptor conformation and ligand orientation determine graded activity. Nat Chem Biol (2010) 1.25
Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol (2013) 1.08
Rho kinase inhibitors: a patent review (2012 - 2013). Expert Opin Ther Pat (2013) 1.07
Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. J Med Chem (2010) 1.05
Regulation of androgen receptor-mediated transcription by RPB5 binding protein URI/RMP. Mol Cell Biol (2011) 1.02
Inhibition of JNK mitochondrial localization and signaling is protective against ischemia/reperfusion injury in rats. J Biol Chem (2012) 1.01
Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains. J Med Chem (2007) 1.01
Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemistry (2002) 1.00
Myotonic dystrophy type 1 RNA crystal structures reveal heterogeneous 1 × 1 nucleotide UU internal loop conformations. Biochemistry (2011) 1.00
The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem Biol (2003) 1.00
Selective inhibition of mitochondrial JNK signaling achieved using peptide mimicry of the Sab kinase interacting motif-1 (KIM1). ACS Chem Biol (2011) 0.98
Blocking c-Jun N-terminal kinase (JNK) translocation to the mitochondria prevents 6-hydroxydopamine-induced toxicity in vitro and in vivo. J Biol Chem (2012) 0.97
Ligand-binding dynamics rewire cellular signaling via estrogen receptor-α. Nat Chem Biol (2013) 0.96
Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson's Disease. ACS Chem Neurosci (2011) 0.96
Synthesis of potent bicyclic bisarylimidazole c-Jun N-terminal kinase inhibitors by catalytic C-H bond activation. J Am Chem Soc (2007) 0.94
The nuclear receptor interacting factor-3 transcriptional coregulator mediates rapid apoptosis in breast cancer cells through direct and bystander-mediated events. Cancer Res (2007) 0.93
Creb coactivators direct anabolic responses and enhance performance of skeletal muscle. EMBO J (2014) 0.91
Thiophene-core estrogen receptor ligands having superagonist activity. J Med Chem (2013) 0.88
Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors. Bioorg Med Chem Lett (2011) 0.87
Insights into PPARgamma from structures with endogenous and covalently bound ligands. Nat Struct Mol Biol (2008) 0.87
Identification and structure-activity relationships of a novel series of estrogen receptor ligands based on 7-thiabicyclo[2.2.1]hept-2-ene-7-oxide. J Med Chem (2012) 0.87
Improved crystallographic structures using extensive combinatorial refinement. Structure (2013) 0.87
Enzyme kinetics and interaction studies for human JNK1β1 and substrates activating transcription factor 2 (ATF2) and c-Jun N-terminal kinase (c-Jun). J Biol Chem (2012) 0.85
Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure-activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides. Org Biomol Chem (2012) 0.85
A crystal structure of a model of the repeating r(CGG) transcript found in fragile X syndrome. Chembiochem (2011) 0.85
The lack of binding of VEK-30, an internal peptide from the group A streptococcal M-like protein, PAM, to murine plasminogen is due to two amino acid replacements in the plasminogen kringle-2 domain. J Biol Chem (2007) 0.84
Kinetic mechanism for human Rho-Kinase II (ROCK-II). Biochemistry (2002) 0.83
First-trimester trophoblast cell model gene response to hypoxia. Am J Obstet Gynecol (2006) 0.83
Synthesis of benzoquinone ansamycin-inspired macrocyclic lactams from shikimic acid. Angew Chem Int Ed Engl (2013) 0.83
The nuclear receptor signalling scaffold: insights from full-length structures. EMBO J (2012) 0.82
Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential. J Med Chem (2015) 0.82
A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases. ACS Chem Biol (2013) 0.81
Convergent synthesis and discovery of a natural product-inspired paralog-selective Hsp90 inhibitor. Org Lett (2011) 0.80
Triaryl-substituted Schiff bases are high-affinity subtype-selective ligands for the estrogen receptor. J Med Chem (2014) 0.80
Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives. J Med Chem (2014) 0.79
Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors. J Med Chem (2015) 0.78
Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor (ER)-Mediated Activities in Breast Cancer Cells. J Med Chem (2017) 0.76
Correction to Design and Synthesis of Highly Potent and Isoform Selective JNK3 Inhibitors: SAR Studies on Aminopyrazole Derivatives. J Med Chem (2016) 0.75
Corrigendum: Full antagonism of the estrogen receptor without a prototypical ligand side chain. Nat Chem Biol (2017) 0.75
Erratum: Full antagonism of the estrogen receptor without a prototypical ligand side chain. Nat Chem Biol (2017) 0.75